Plasma levels of 13,14-dihydro-15-keto PGE2 after vaginal application of a new PGE2 film.
To determine the release and absorption profile of prostaglandin E2 from a new vaginal film formulation containing 850 micrograms PGE2, serial plasma levels of 13,14-dihydro-15-keto PGE2 were measured by radioimmunoassay in pregnant women between 16 and 18 weeks gestation. A control group, using placebo vaginal film was included in the study. There was a somewhat uniform increase in the plasma levels of the PGE2 metabolite, reaching peak levels between 4 and 6 hours after application of the film. The findings suggest that this drug formulation could be used clinically when slow constant release of the prostaglandin is required over a period of hours such as in pre-induction cervical ripening of term pregnancy.
D000028:Abortion, Induced; D003692:Delayed-Action Preparations; D015232:Dinoprostone / Q000031:analogs & derivatives; D005260:Female; D006801:Humans; D011247:Pregnancy; D011262:Pregnancy Trimester, Second; D011458:Prostaglandins E / Q000008:administration & dosage* / Q000097:blood*; D014621:Vagina
D003692:Delayed-Action Preparations; D011458:Prostaglandins E; C025087:15-keto-13,14-dihydroprostaglandin E2; D015232:Dinoprostone